Ayala Pharmaceuticals Inc. (AYLA): Price and Financial Metrics


Ayala Pharmaceuticals Inc. (AYLA): $0.50

0.03 (+5.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AYLA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AYLA POWR Grades

  • Growth is the dimension where AYLA ranks best; there it ranks ahead of 64.21% of US stocks.
  • AYLA's strongest trending metric is Sentiment; it's been moving down over the last 60 days.
  • AYLA's current lowest rank is in the Momentum metric (where it is better than 3.69% of US stocks).

AYLA Stock Summary

  • AYLA has a market capitalization of $7,054,666 -- more than approximately only 2.15% of US stocks.
  • The ratio of debt to operating expenses for AYALA PHARMACEUTICALS INC is higher than it is for about merely 0.48% of US stocks.
  • Revenue growth over the past 12 months for AYALA PHARMACEUTICALS INC comes in at -48.48%, a number that bests just 3.95% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AYALA PHARMACEUTICALS INC are VTGN, INO, MEIP, GSIT, and OGEN.
  • Visit AYLA's SEC page to see the company's official filings. To visit the company's web site, go to www.ayalapharma.com.

AYLA Valuation Summary

  • AYLA's price/sales ratio is 4.6; this is 119.05% higher than that of the median Healthcare stock.
  • AYLA's EV/EBIT ratio has moved up 9.6 over the prior 33 months.

Below are key valuation metrics over time for AYLA.

Stock Date P/S P/B P/E EV/EBIT
AYLA 2023-01-13 4.6 1.0 -0.2 0.1
AYLA 2023-01-12 4.5 1.0 -0.2 0.1
AYLA 2023-01-11 4.7 1.0 -0.2 0.1
AYLA 2023-01-10 4.4 0.9 -0.2 0.1
AYLA 2023-01-09 4.4 0.9 -0.2 0.1
AYLA 2023-01-06 3.9 0.8 -0.2 0.1

AYLA Price Target

For more insight on analysts targets of AYLA, see our AYLA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.00 Average Broker Recommendation 1.42 (Moderate Buy)

AYLA Stock Price Chart Interactive Chart >

Price chart for AYLA

AYLA Price/Volume Stats

Current price $0.50 52-week high $7.31
Prev. close $0.48 52-week low $0.36
Day low $0.44 Volume 137,700
Day high $0.57 Avg. volume 76,300
50-day MA $0.53 Dividend yield N/A
200-day MA $1.37 Market Cap 7.46M

Ayala Pharmaceuticals Inc. (AYLA) Company Bio


Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.


AYLA Latest News Stream


Event/Time News Detail
Loading, please wait...

AYLA Latest Social Stream


Loading social stream, please wait...

View Full AYLA Social Stream

Latest AYLA News From Around the Web

Below are the latest news stories about AYALA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AYLA as an investment opportunity.

Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (C

Yahoo | November 17, 2022

Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibito

Yahoo | November 16, 2022

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 4, 2022

Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study presented at ESMO demonstrated substantial anti-tumor activity for AL102 as monotherapy and supports continued development AL102 granted Fast Track designation by U.S. FDA for the treatment of progressing desmoid tumors REHOVOT, Israel

Yahoo | November 4, 2022

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement. The merger would result in a combined company focusing predominantly on developing and commercializing Ayala's lead program AL102 to treat desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer. Ayala's lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors. The combined company has the cash to advance the combined p

Yahoo | October 19, 2022

Read More 'AYLA' Stories Here

AYLA Price Returns

1-mo -1.98%
3-mo -13.79%
6-mo -62.96%
1-year -91.09%
3-year N/A
5-year N/A
YTD 24.97%
2022 -95.30%
2021 -22.64%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8316 seconds.